Reactive oxygen species mediate high glucose-induced heparanase-1 production and heparan sulphate proteoglycan degradation in human and rat endothelial cells: A potential role in the pathogenesis of atherosclerosis

Diabetologia

Volumn 54, Issue 6, 2011, Pages 1527-1538

  Rao, G ^a   Ding, H G ^a   Huang, W ^a   Le, D ^a   Maxhimer, J B ^a,c   Oosterhof, A ^b   Van Kuppevelt, T ^b   Lum, H ^a   Lewis, E J ^a   Reddy, V ^a   Prinz, R A ^a,d   Xu, X ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Atherosclerosis; Diabetes; Endothelial cells; Heparan sulphate; Heparanase; Hyperglycaemia; Macrophage; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; GLUCOSE; GLUTATHIONE; HEPARAN SULFATE; HEPARANASE; HEPARANASE 1; HYDROGEN PEROXIDE; MESSENGER RNA; PROTEOGLYCAN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; BETA GLUCURONIDASE; PROTEOHEPARAN SULFATE; STREPTOZOCIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY WALL; ARTICLE; CAROTID ATHEROSCLEROSIS; CELL LEVEL; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETOGENESIS; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME SYNTHESIS; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; ATHEROSCLEROSIS; CELL LINE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; MIDDLE AGED; PATHOLOGY; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ATHEROSCLEROSIS; CELL LINE; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; GLUCOSE; GLUCURONIDASE; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; HYDROGEN PEROXIDE; HYPERGLYCEMIA; MALE; MIDDLE AGED; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; STREPTOZOCIN;

EID: 80052521778     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2110-z     Document Type: Article

References (45)

1. Esko JD, Lindahl U (2001) Molecular diversity of heparan sulfate. J Clin Invest 108:169-173 (Pubitemid 32656238)
2. Iozzo RV (2001) Heparan sulfate proteoglycans: intricate molecules with intriguing functions. J Clin Invest 108:165-167
3. Perrimon N, Bernfield M (2000) Specificities of heparan sulphate proteoglycans in developmental processes. Nature 404:725-728 (Pubitemid 30212391)
4. Stringer SE, Gallagher JT (1997) Specific binding of the chemokine platelet factor 4 to heparan sulfate. J Biol Chem 272:20508-20514 (Pubitemid 27355607)
5. Stringer SE, Gallagher JT (1997) Heparan sulphate. Int J Biochem Cell Biol 29:709-714 (Pubitemid 27323158)
6. Gallagher JT (2001) Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 108:357-361
7. Iozzo RV, Cohen IR, Grassel S, Murdoch AD (1994) The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 302:625-639 (Pubitemid 24289294)
8. Duan W, Paka L, Pillarisetti S (2005) Distinct effects of glucose and glucosamine on vascular endothelial and smooth muscle cells: evidence for a protective role for glucosamine in atherosclerosis. Cardiovasc Diabetol 4:16
9. Vogl-Willis CA, Edwards IJ (2004) High-glucose-induced structural changes in the heparan sulfate proteoglycan, perlecan, of cultured human aortic endothelial cells. Biochim Biophys Acta 1672:36-45 (Pubitemid 38410966)
10. Wasty F, Alavi MZ, Moore S (1993) Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus. Diabetologia 36:316-322 (Pubitemid 23106015)
11. Edwards IJ, Wagner JD, Vogl-Willis CA, Litwak KN, Cefalu WT (2004) Arterial heparan sulfate is negatively associated with hyperglycemia and atherosclerosis in diabetic monkeys. Cardiovasc Diabetol 3:6
12. Pillarisetti S (2000) Lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan) and atherogenicity. Trends Cardiovasc Med 10:60-65
13. Olsson U, Ostergren-Lunden G, Moses J (2001) Glycosaminoglycan- lipoprotein interaction. Glycoconj J 18:789-797
14. Conde-Knape K (2001) Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications. Diabetes Metab Res Rev 17:412-421
15. Pillarisetti S, Paka L, Obunike JC, Berglund L, Goldberg IJ (1997) Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J Clin Invest 100:867-874 (Pubitemid 27371705)
16. van den Hoven MJ, Wijnhoven TJ, Li JP et al (2008) Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria. Kidney Int 73:278-287
17. van den Hoven MJ, Rops AL, Bakker MA et al (2006) Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 70:2100-2108 (Pubitemid 44871372)
18. Maxhimer JB, Somenek M, Rao G et al (2005) Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 54:2172-2178 (Pubitemid 40911281)
19. Kramer A, van den Hoven M, Rops A et al (2006) Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system. J Am Soc Nephrol 17:2513-2520 (Pubitemid 44300967)
20. Han J, Woytowich AE, Mandal AK, Hiebert LM (2007) Heparanase upregulation in high glucose-treated endothelial cells is prevented by insulin and heparin. Exp Biol Med (Maywood) 232:927-934 (Pubitemid 47026799)
21. Lum H, Qiao J, Walter RJ et al (2003) Inflammatory stress increases receptor for lysophosphatidylcholine in human microvascular endothelial cells. Am J Physiol Heart Circ Physiol 285:H1786-H1789 (Pubitemid 37169536)
22. Xu X, Rao G, Quiros RM et al (2007) In vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas. Loss of cell surface HS suppresses fibroblast growth factor 2-mediated cell signaling and proliferation. J Biol Chem 282:2363-2373 (Pubitemid 47076771)
23. Wijnhoven TJ, van den Hoven MJ, Ding H et al (2008) Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy. Diabetologia 51:372-382
24. Xu X, Ding J, Rao G et al (2007) Estradiol induces heparanase-1 expression and heparan sulphate proteoglycan degradation in human endometrium. Hum Reprod 22:927-937
25. Quiros RM, Rao G, Plate J et al (2006) Elevated serum heparanase-1 levels in patients with pancreatic carcinoma are associated with poor survival. Cancer 106:532-540 (Pubitemid 43157615)
26. Jiang P, Kumar A, Parrillo JE et al (2002) Cloning and characterization of the human heparanase-1 (HPR1) gene promoter: role of GA-binding protein and Sp1 in regulating HPR1 basal promoter activity. J Biol Chem 277:8989-8998 (Pubitemid 34952971)
27. Eustice DC, Feldman PA, Colberg-Poley AM, Buckery RM, Neubauer RH (1991) A sensitive method for the detection of beta-galactosidase in transfected mammalian cells. Biotechniques 11 (739-740):742-743
28. Francis DJ, Parish CR, McGarry M et al (2003) Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide PI-88: phospHomannopentaose sulfate directly binds FGF-2, blocks cellular signaling, and inhibits proliferation. Circ Res 92:e70-e77
29. Xu X, Quiros RM, Maxhimer JB et al (2003) Inverse correlation between heparan sulfate deposition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis. Clin Cancer Res 9:5968-5979 (Pubitemid 38018083)
30. Rao G, Liu D, Xing M, Tauler J, Prinz RA, Xu X (2010) Induction of heparanase-1 expression by mutant b-raf kinase: role of GA binding protein in heparanase-1 promoter activation. Neoplasia 12:946-956
31. Abboud-Jarrous G, Rangini-Guetta Z, Aingorn H et al (2005) Site-directed mutagenesis, proteolytic cleavage and activation. J Biol Chem 280:13568-13575 (Pubitemid 40517249)
32. Zetser A, Levy-Adam F, Kaplan V et al (2004) Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 117:2249-2258 (Pubitemid 38807493)
33. Nadav L, Eldor A, Yacoby-Zeevi O et al (2002) Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts. J Cell Sci 115:2179-2187 (Pubitemid 34746383)
34. Maxhimer JB, Quiros RM, Stewart R et al (2002) Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery 132:326-333 (Pubitemid 35024780)
35. Wang F, Kim MS, Puthanveetil P et al (2009) Endothelial heparanase secretion after acute hypoinsulinemia is regulated by glucose and fatty acid. Am J Physiol Heart Circ Physiol 296: H1108-H1116
36. van den Hoven MJ, Waanders F, Rops AL et al (2009) Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species. Nephrol Dial Transplant 24:2637-2645
37. Teoh ML, Fitzgerald MP, Oberley LW, Domann FE (2009) Overexpression of extracellular superoxide dismutase attenuates heparanase expression and inhibits breast carcinoma cell growth and invasion. Cancer Res 69:6355-6363
38. Raats CJ, van Den Born J, Berden JH (2000) Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 57:385-400 (Pubitemid 30430630)
39. Moseley R, Waddington R, Evans P, Halliwell B, Embery G (1995) The chemical modification of glycosaminoglycan structure by oxygen-derived species in vitro. Biochim Biophys Acta 1244:245-252
40. Stocker R, Keaney JF Jr (2004) Role of oxidative modifications in atherosclerosis. Physiol Rev 84:1381-1478 (Pubitemid 39302636)
41. Edovitsky E, Lerner I, Zcharia E, Peretz T, Vlodavsky I, Elkin M (2006) Role of endothelial heparanase in delayed-type hypersensitivity. Blood 107:3609-3616
42. Chen G, Wang D, Vikramadithyan R et al (2004) Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry 43:4971-4977 (Pubitemid 38544450)
43. Baker AB, Groothuis A, Jonas M et al (2009) Heparanase alters arterial structure, mechanics, and repair following endovascular stenting in mice. Circ Res 104:380-387
44. Baker AB, Chatzizisis YS, Beigel R et al (2010) Regulation of heparanase expression in coronary artery disease in diabetic, hyperlipidemic swine. Atherosclerosis 213:436-442
45. Cohen-Mazor M, Sela S, Mazor R et al (2008) Are primed polymorphonuclear leukocytes contributors to the high heparanase levels in hemodialysis patients? Am J Physiol Heart Circ Physiol 294:H651-H658 (Pubitemid 351253276)